Overview

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Status:
Recruiting
Trial end date:
2023-06-26
Target enrollment:
Participant gender:
Summary
Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Phase:
Phase 3
Details
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.
Treatments:
Dapagliflozin
Metformin